Results 121 to 130 of about 256,425 (387)
Novel Antiplatelet Agents in Cardiovascular Disease
Antiplatelet therapy reduces atherothrombotic risk and has therefore become a cornerstone in the treatment of cardiovascular disease. Aspirin, adenosine diphosphate P2Y12 receptor antagonists, glycoprotein IIb/IIIa inhibitors, and the thrombin receptor ...
M. Tscharre +2 more
semanticscholar +1 more source
ABSTRACT Background High‐altitude populations typically exhibit elevated hemoglobin (Hb) levels due to chronic hypoxic exposure; however, the impact of this elevation on the risk of ST‐segment elevation myocardial infarction (STEMI) remains unclear. Existing evidence is primarily derived from low‐altitude populations and cannot be directly extrapolated
Jing Li +10 more
wiley +1 more source
Disclosure and adverse effects of complementary and alternative medicine used by hospitalized patients in the North East of England [PDF]
Objectives: This study aimed to investigate the prevalence, disclosure and adverse effects of complementary and alternative medicine (CAM) use in hospitalised patients, and to explore the associations between patients’ perceived side-effects and relevant
Baqir, wasim +3 more
core +2 more sources
The risk of endoscopy in patients on antithrombotics depends on the risks of procedural haemorrhage versus thrombosis due to discontinuation of therapy. P2Y12 receptor antagonists (clopidogrel, prasugrel, ticagrelor) For low-risk endoscopic procedures we
A. Veitch +10 more
semanticscholar +1 more source
Nationwide Analysis of PCI After TAVR From the Netherlands Heart Registration
ABSTRACT Background Percutaneous coronary intervention (PCI) after transcatheter aortic valve replacement (TAVR) has gained interest as concomitant coronary artery disease (CAD) is now often treated conservatively before TAVR, and TAVR is increasingly used in younger patients with longer life expectancies. Therefore, more contemporary data on PCI after
Hugo M. Aarts +7 more
wiley +1 more source
NOVEL APPROACH TO ANTITHROMBOTIC TREATMENT OF ACUTE CORONARY PATIENTS WITH RIVAROXABAN
Antithrombotic treatment of acute coronary syndrome leads to much better outcomes of the disease. The article focuses on the arguments and evidence for the addition to antiplatelet drugs the rivaroxaban 2,5 mg two times per day for secondary prevention ...
I. N. Bokarev, A. V. Golub
doaj +1 more source
Antiplatelet Therapy in Ischemic Stroke and Transient Ischemic Attack.
Stroke is a leading cause of mortality and disability worldwide. Initial manifestations of acute cerebral ischemia, such as ischemic stroke and transient ischemic attack (TIA), are often followed by recurrent vascular events, including recurrent stroke ...
D. Hackam, J. Spence
semanticscholar +1 more source
ABSTRACT Coronary perforations are a dreaded complication for any interventional cardiologist. The treatment of this complication is exceptionally difficult when it occurs in a coronary bifurcation. While a conservative approach or a balloon occlusion might be sufficient in some cases, additional treatment is sometimes necessary.
Jakob U. Lindner +3 more
wiley +1 more source
Background: Stent-assisted coil embolization (SACE) is a common endovascular technique for managing intracranial aneurysms. The permanent presence of a stent inside the cerebral artery necessitates the postoperative use of antiplatelets.
Mohammed Maan Al-Salihi +6 more
doaj +1 more source
Different Antiplatelet Strategies for Radial Artery Protection After Transradial Coronary Angiography—A Prospective Observational Cohort Study [PDF]
Zheng Qin +4 more
openalex +1 more source

